Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia

Published:2021-08-16 Issue:5 Volume:39 Page:687-696
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Mesegué Montserrat¹²^ORCID,Alonso‐Saladrigues Anna¹²,Pérez‐Jaume Sara³,Comes‐Escoda Ariadna⁴,Dapena José Luís¹²,Faura Anna¹²,Conde Nuria¹²,Català Albert¹²⁵,Ruiz‐Llobet Anna¹²,Zapico‐Muñiz Edgar⁶,Camós Mireia²³⁷,Rives Susana¹²⁵

Affiliation:

1. Pediatric Hematology and Oncology Departments Hospital Sant Joan de Déu University of Barcelona Barcelona Spain

2. Leukemia and other Pediatric Hemopathies Developmental Tumor Biology Group Institut de Recerca Hospital Sant Joan de Déu Barcelona Barcelona Spain

3. Developmental Tumor Biology Laboratory Institut de Recerca Sant Joan de Déu Barcelona Barcelona Spain

4. Oncohematology Unit Pharmacy Department Hospital Sant Joan de Déu University of Barcelona Barcelona Spain

5. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Instituto de Salud Carlos III Madrid Spain

6. Biochemistry Department Hospital de la Santa Creu i Sant Pau Barcelona Spain

7. Hematology Laboratory Hospital Sant Joan de Déu University of Barcelona Barcelona Spain

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2914

Reference38 articles.

1. Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia

2. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

3. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01

4. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia

5. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia;Thrombosis and Haemostasis;2024-04-29

2. Comparison of efficacy and safety of different asparaginases in adult acute lymphoblastic leukemia based on nano-magnetic beads immunoassay;American Journal of Translational Research;2024

3. Mathematical modeling of leukemia chemotherapy in bone marrow;Mathematical Modelling of Natural Phenomena;2023

4. Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL‐SEHOP‐PETHEMA‐2013;Journal of Thrombosis and Haemostasis;2022-06

5. Asparaginase drugs: a new view of the mechanism of action, side effects and experience in BFM (Berlin–Frankfurt–Munster) protocols;Russian Journal of Pediatric Hematology and Oncology;2022-01-20